Radiation plus drug cocktail shows promise for resistant lung cancer
NCT ID NCT06775743
First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study tests whether adding precise radiation (SBRT) to a four-drug combination (sintilimab, bevacizumab, and chemotherapy) can help people with advanced EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy. About 53 participants will receive the drug combo first, then personalized radiation to any remaining tumors. Researchers will measure how long the cancer stays under control and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab, bevacizumab, platinum-doublet chemotherapy, and stereotactic body radiotherapy
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of advanced lung cancer that has stopped responding to standard pills.
What could go wrong
This is a small, early-phase study (53 people) with no control group, so results may not apply broadly. The combination therapy can cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.